Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | FAAH | O00519 | 2/20 | 0.62 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.62 |
| ▸ | PPARA | Q07869 | 2/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | ADH1B | P00325 | 1/20 | 0.52 |
| ▸ | ADH1C | P00326 | 1/20 | 0.52 |
| ▸ | ADH1A | P07327 | 1/20 | 0.52 |
| ▸ | ADH4 | P08319 | 1/20 | 0.52 |
| ▸ | ADH7 | P40394 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9480001 | 1.00 | TSHR (0.65) | TSHRALDH1A1FAAHTRPV1PPARA | |
| SCHEMBL518802 | 1.00 | TSHR (0.65) | TSHRALDH1A1FAAHTRPV1PPARA | |
| SCHEMBL9208641 | 1.00 | TSHR (0.65) | TSHRALDH1A1FAAHTRPV1PPARA | |
| SCHEMBL6677501 | 1.00 | TSHR (0.65) | TSHRALDH1A1FAAHTRPV1PPARA | |
| SCHEMBL519455 | 1.00 | TSHR (0.65) | TSHRALDH1A1FAAHTRPV1PPARA | |
| SCHEMBL11786437 | 1.00 | TSHR (0.65) | TSHRALDH1A1FAAHTRPV1PPARA | |
| SCHEMBL23117202 | 1.00 | TSHR (0.65) | TSHRALDH1A1FAAHTRPV1PPARA | |
| SCHEMBL518800 | 1.00 | TSHR (0.65) | TSHRALDH1A1FAAHTRPV1PPARA | |
| SCHEMBL554166 | 1.00 | TSHR (0.65) | TSHRALDH1A1FAAHTRPV1PPARA | |
| SCHEMBL22063916 | 1.00 | TSHR (0.65) | TSHRALDH1A1FAAHTRPV1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170036990-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | SILENCE THERAPEUTICS AG (DE) | 2017-02-09 | — | — | US | claimed |
| US-20140329885-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | SILENCE THERAPEUTICS GMBH (DE) | 2014-11-06 | — | — | US | claimed |
| US-20120065138-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | SILENCE THERAPEUTICS AG (DE) | 2012-03-15 | — | — | US | claimed |
| EP-2105411-B1 | A method of exfoliating a layered silicate | CRYOVAC INC (US) | 2012-03-14 | — | — | EP | claimed |
| EP-2105411-A1 | Intercalated layered silicate | Cryovac, Inc. (US) | 2009-09-30 | — | — | EP | claimed |
| US-20080274116-A1 | Lipids, Lipid Complexes and Use Thereof | SILENCE THERAPEUTICS AG (DE) | 2008-11-06 | — | — | US | claimed |
| EP-1945706-A1 | INTERCALATED LAYERED SILICATE | Cryovac, Inc. (US) | 2008-07-23 | — | — | EP | claimed |
| JP-2007536324-A | — | — | 2007-12-13 | — | — | JP | claimed |
| EP-1771206-A2 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | atugen AG (DE) | 2007-04-11 | — | — | EP | claimed |
| WO-2007024564-A1 | INTERCALATED LAYERED SILICATE | CRYOVAC, INC. (US) | 2007-03-01 | — | — | WO | claimed |
| WO-2005105152-A2 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | ATUGEN AG (DE) | 2005-11-10 | — | — | WO | claimed |
| EP-1771206-B1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | SILENCE THERAPEUTICS GMBH (DE) | 2018-04-11 | — | — | EP | disclosed |
| US-20170036990-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | SILENCE THERAPEUTICS AG (DE) | 2017-02-09 | — | — | US | disclosed |
| US-9486538-B2 | Lipids, lipid complexes and use thereof | SILENCE THERAPEUTICS GMBH (DE) | 2016-11-08 | — | — | US | disclosed |
| US-9387262-B2 | Coated lipid complexes and their use | SILENCE THERAPEUTICS GMBH (DE) | 2016-07-12 | — | — | US | disclosed |
| WO-2006069782-A2 | LIPID COMPLEXES COATED WITH PEG AND THEIR USE | SILENCE THERAPEUTICS AG. (DE) | 2006-07-06 | — | — | WO | disclosed |
| WO-2005105152-A2 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | ATUGEN AG (DE) | 2005-11-10 | — | — | WO | disclosed |
| EP-0649883-B1 | Pigment compositions | CIBA SC HOLDING AG (CH) | 2001-08-08 | — | — | EP | disclosed |
| US-5614013-A | Pigment compositions | CIBA-GEIGY CORPORATION (US) | 1997-03-25 | — | — | US | disclosed |
| EP-0649883-A1 | Pigment compositions | CIBA-GEIGY AG (CH) | 1995-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065138-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | MGLL, LIPA, SGMS1 | TSHR 1371/4885ALDH1A1 2001/4885FAAH 167/4885 |
| US-20170036990-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | MGLL, LIPA, LIPC | TSHR 1379/4885ALDH1A1 2195/4885FAAH 185/4885 |
| US-20080274116-A1 | Lipids, Lipid Complexes and Use Thereof | MGLL, LIPA, SGMS1 | TSHR 1296/4885ALDH1A1 1829/4885FAAH 153/4885 |
| US-20140329885-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | MGLL, LIPA, LIPC | TSHR 1379/4885ALDH1A1 2195/4885FAAH 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.